Immuneering Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
3.7%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$1.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Preliminary Phase 2 Data: Atebimetinib + Libtayo in NSCLC | 31 Dec 2027 |
| Topline Overall Survival Readout for Phase 3 MAPKeeper 301 Trial | 30 Jun 2028 |
Monitoring Framework
Key Performance Indicators
Median Overall Survival (OS) in First-Line Metastatic Pancreatic Cancer (Phase 2a) Annually17.3Target: Exceed historical standard of care benchmark of 8.5 months
Cash, Cash Equivalents, and Marketable Securities Quarterly198.6MTarget: Maintain sufficient runway to fund operations into 2029
Quarterly Research and Development (R&D) Expenses Quarterly10.6MTarget: Optimize clinical spend while advancing lead programs
Watch Items
- MAPKeeper 301 Phase 3 Trial Patient Enrollment and Site InitiationTrigger: Slower-than-expected global site activation or patient recruitmentAction: Expand clinical trial footprint globally and increase investigator engagement
- Phase 2 Trial Initiation of Atebimetinib + Libtayo (cemiplimab) in NSCLCTrigger: Delay in dosing the first patient beyond the second half of 2026Action: Review clinical supply chain and operational readiness with partner Regeneron
- Cash Burn Rate and Runway SustainabilityTrigger: Quarterly net loss exceeding $20 million or runway shortening to under 2 yearsAction: Evaluate strategic partnerships, non-dilutive funding, or capital market opportunities
Research as of 19 Jun 2026